Cancer Hospital, Chinese Academy of Medical Sciences
The CAMS Cancer Hospital is China's national cancer centre, leading regulatory-grade trials of domestic ADCs and PD-1 antibodies.
National Cancer Center of China; SKB264 (sac-TMT), disitamab vedotin, and many pivotal Chinese trials.
- National trials
- ADC development
Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval.
A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.
Runs China's national cancer centre and the registry that reports the country's cancer statistics.
Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.
Principal investigator of ESCORT, the trial that established camrelizumab in oesophageal squamous cell carcinoma.
A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.